In data supporting FDA approval, 48.1% implanted with Prodeon’s Urocross saw International Prostate Symptom Score ...

Prodeon Medical, a privately held medical device company focused on advancing minimally invasive therapies for urologic diseases, today announced it has received U.S. Food and Drug Administration (FDA ...

Image courtesy of Prodeon Medical] Prodeon Medical announced today that it received FDA 510(k) clearance for its Urocross ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Procept BioRobotics today announced the international rollout of its next-generation Hydros robotic system for Aquablation ...

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat benign prostatic hyperplasia (BPH).

Benign prostatic hyperplasia (BPH) is associated with elevated risks for depression and anxiety, with a causal link to depression supported by genetic evidence, according to a study published online ...

An enlarged prostate—also known as benign prostatic hyperplasia (BPH)—is a natural sign of aging that affects half of all men over the age of 40. The good news is this condition does not increase your ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...